Market Overview
Size, disease cost, and pork demand
- Brevintel analysis values the swine vaccines market at USD 1.6 billion in 2025 ($1.6B), with a path from about USD 1.7 billion in 2026 to USD 2.9 billion by 2035 ($2.9B) at a 6.3% CAGR.
- The detailed series moves from USD 1,578.2 million in 2025 to USD 2,876.1 million in 2035, confirming the same $1.6B to $2.9B expansion at 6.3%.
- Merck led with over 38.5% share in 2025; Zoetis, Boehringer Ingelheim International, Merck, Ceva, and Elanco Animal Health Incorporated collectively held 95%.
- Iowa State University estimated that PRRS caused roughly USD 1.2 billion in annual U.S. pork-production losses during 2016–2020, with that veterinary assessment dated 2021.
- African swine fever had been reported by 83 countries as of January 2025, and its acute form can cause mortality of up to 100%.
- Pork accounts for more than 35% of global meat intake, so herd-level disease events quickly become food-supply and processor-planning issues.
- OECD-FAO projects global pork demand to rise from an average of 110.5 million tons in 2019–2021 to 128.9 million tons by 2031.
- Asian pork demand is projected to increase from 61.4 million tons to 76 million tons over the same period, a 24% rise by 2031.
Why prevention spend is rising
- Intensive pork systems use vaccination to protect herd performance, limit treatment disruption, and keep supply planning predictable.
- Brevintel analysis treats the move from USD 1,578.2 million to USD 2,876.1 million as more than routine herd expansion.
- PRRS losses near USD 1.2 billion a year and ASF’s 83-country footprint make prevention cheaper than outbreak disruption for many producers.
- The 6.3% outlook through 2035 is supported by a larger installed animal base plus recurring endemic and transboundary disease risk.
- Suppliers with proven protection against economically consequential pathogens, herd-level service, and scalable manufacturing are better placed than price-only competitors.
- Inactivated/killed vaccines already generated USD 908 million in 2025, giving combination and delivery upgrades a large installed base.
Market Dynamics
Demand drivers
- ASF across 83 countries and mortality of up to 100% make outbreak preparedness a supply-chain issue as well as a veterinary one.
- Vaccination demand also reflects movement restrictions, depopulation risk, interrupted breeding cycles, and delayed market access.
- OECD-FAO expects Asian pork demand to grow by 24% by 2031, enlarging the animal and site base that needs disease prevention.
- Merck Animal Health’s Sequivity platform uses RNA particle technology to create herd-specific prescription vaccines in a 10–16-week window.
- Combination products, custom-vaccine platforms, and emerging mRNA approaches can reduce handling events or adapt faster to herd-specific pathogen profiles.
- AI tools may help organize pathogen surveillance, prioritize antigen candidates, and manage documentation, subject to validation and regulatory acceptance.
- WOAH still lists biosecurity, surveillance, early detection, and movement control as essential ASF measures, so vaccines sit inside a wider risk system.
- Suppliers that pair protocols with diagnostics, administration guidance, and biosecurity planning become more embedded in producer programs.
Constraints
- Development requires pathogen characterization, safety and efficacy work, manufacturing validation, and jurisdiction-specific regulatory files.
- Those costs weigh heaviest for fragmented disease needs or smaller regional markets.
- Merck received a U.S. license for Circumvent CML in 2022 before announcing market availability in June 2023, showing the gap after licensing.
- Veterinary biologics need controlled storage and last-mile delivery, which limits uptake where rural logistics or clinic storage are inconsistent.
- Thermostable formulations can improve access only if antigen stability and regulatory compliance are preserved.
- The European Medicines Agency pathway for Cirbloc M Hyo, with an EPAR dated September 13, 2024, shows the evidence bar for combination swine vaccines.
- Brevintel analysis still sees the 6.3% trajectory as achievable because disease losses and pork expansion create recurring demand.
- Cold-chain and regulatory capacity will constrain uptake most where disease risk is high but veterinary distribution remains uneven.
Segmentation Analysis
Type
- Inactivated/killed vaccines generated USD 908 million in 2025, reflecting safety, formulation stability, and fit with structured herd-health protocols.
- That installed base supports differentiated combinations and improved delivery rather than replacing the platform.
- Live attenuated vaccines accounted for 34.5% of the market in 2025 and are projected to expand at approximately 6.6% CAGR.
- Their role is strongest where immune-response characteristics and disease-control objectives justify live platforms.
- Viral vector, mRNA, and other types remain development areas where faster antigen adaptation or improved strain targeting is needed.
- Adoption of next-generation platforms will depend on evidence, manufacturing scale, and veterinary-practice acceptance.
Application
- Viral infections represented 66.2% of the market in 2025 and are projected to grow at approximately 6.4% CAGR.
- PRRS, porcine circovirus-associated disease, and ASF-related biosecurity keep viral control central to purchasing.
- Bacterial vaccines still support respiratory and enteric programs, while parasitic and other uses remain more specialized.
- The mix favors products that cut the operational complexity of covering several economically relevant pathogens.
- Combination vaccines are especially useful where respiratory, reproductive, or enteric challenges overlap in one production system.
Route of administration
- Injection vaccines generated USD 1.2 billion in 2025 and are projected to reach USD 2.2 billion by 2035.
- Injectables keep dose control and multi-antigen compatibility, but they add labor and handling in large facilities.
- Oral vaccines are projected to grow at approximately 6.6% CAGR, supported by lower handling intensity for large groups.
- Immersion and spray formats remain relevant where group-level administration fits the workflow.
- Route choice depends on pathogen biology, animal age, facility practice, labor, and required administration precision.
Distribution channel
- Veterinary hospital pharmacies held 77.1% of the market in 2025, reflecting oversight, prescription control, storage, and protocol design.
- Retail pharmacies add supply where products and rules allow, but they are more limited for specialized biologics.
- E-commerce is projected to grow at approximately 6.8% CAGR where digital ordering complements veterinary authorization and cold-chain fulfillment.
- Brevintel analysis of veterinarian feedback, the USD 908 million inactivated/killed segment, and the 34.5% live attenuated share points to established platforms retaining value.
- Incremental growth is shifting toward combinations and adaptable technologies that reduce intervention complexity.
Regional Outlook
North America
- North America generated USD 682.6 million in 2025 and is projected to reach USD 1,189.2 million by 2035, growing at approximately 5.8% CAGR.
- USDA inventory data indicate that the United States has more than 70 million hogs, supporting protocol-driven vaccine demand.
- The U.S. market was valued at USD 635.4 million in 2025, compared with USD 606 million in 2024, USD 578.7 million in 2023, and USD 553.3 million in 2022.
- Integrator systems, veterinary networks, and regulatory infrastructure favor structured protocols and combination products.
- Recent U.S. activity includes Merck’s Circumvent CML and Boehringer Ingelheim’s INGELVAC CIRCOFLEX AD, launched September 3, 2025 for advanced PCV2 protection.
Europe
- Europe generated USD 430.2 million in 2025, supported by a production base estimated at approximately one-fifth of global pork output.
- Demand is shaped by mature herd-health practice, regulatory scrutiny, and differentiation through combination vaccines.
- Germany, the UK, France, Spain, Italy, and the Netherlands are important markets in the regional veterinary-health landscape.
- EU authorization of Ceva’s Cirbloc M Hyo and Virbac’s 2025 French launch of a combined porcine parvovirus and leptospirosis vaccine show continued respiratory and reproductive focus.
Asia Pacific, Latin America, and Middle East & Africa
- Asia Pacific is projected to record approximately 7% CAGR through 2035, the fastest regional expansion rate.
- OECD-FAO forecasts Asian pork demand to increase from 61.4 million tons to 76 million tons by 2031.
- China, India, Japan, Australia, and South Korea each present distinct production, disease, regulatory, and distribution conditions.
- China reported Asia’s first ASF occurrence in August 2018, elevating surveillance, biosecurity, and coordinated control.
- Brazil, Mexico, and Argentina provide a meaningful Latin American production base tied to export orientation, consolidation, and disease management.
- South Africa and the UAE are the principal Middle East and Africa country scope; ASF across multiple African countries keeps prevention and movement control central.
- Variable cold-chain infrastructure and uneven specialist veterinary access make resilient local distribution essential in MEA.
- Brevintel analysis contrasts North America’s USD 682.6 million 2025 depth with Asia Pacific’s approximately 7% growth and greater disease-control urgency.
Competitive Landscape
Structure and product direction
- The market is concentrated, with the top five participants estimated to account for approximately 95% of global revenue.
- Merck led with over 38.5% share in 2025, while Zoetis, Boehringer Ingelheim International, Merck, Ceva, and Elanco Animal Health Incorporated held 95% together.
- Scale funds antigen research, regulatory filings, manufacturing validation, cold-chain distribution, and veterinary technical support.
- Boehringer Ingelheim, Ceva Santé Animale, and Merck Animal Health illustrate competition through multi-antigen and disease-specific innovation.
- The Cirbloc M Hyo EPAR dated September 13, 2024 shows how a single administration can reduce handling and simplify protocols when protection matches the herd profile.
- Pricing stays tied to disease-risk cost, product breadth, veterinary involvement, and logistics rather than unit vaccine price alone.
- Smaller participants compete through local registration knowledge, targeted pathogen coverage, and proximity to producer channels.
Integrated producers
- Merck Animal Health
- Zoetis
- Boehringer Ingelheim
- Elanco Animal Health Incorporated
- Ceva Santé Animale
Specialty suppliers
- Addison Biological Laboratory
- Bioveta
- Colorado Serum Company
- HIPRA S.A.
- Indian Immunologicals
- Biogénesis Bagó
- Vaxxinova (EW Group)
- Vibac